Literature DB >> 18677072

Factors associated with zidovudine receipt and prenatal care among HIV-infected pregnant women in New Jersey.

Diane J Abatemarco1, Janet M Catov, Helene Cross, Cristine Delnevo, Alice Hausman.   

Abstract

Despite reductions in perinatal HIV transmission, cases continue to occur. To determine factors associated with zidovudine (ZDV) receipt among HIV-infected pregnant women we merged three data sets for women in New Jersey in 1995-1997, identifying 395 HIV-infected pregnant women. Half received two arms of ZDV prophylaxis. Attendance at five or more prenatal visits was the strongest independent factor related to ZDV receipt (OR 6.37, 95% CI 3.84, 10.57). Half (49.0%) had limited prenatal care. AIDS diagnosis, race/ethnicity, and drug use were also independently related to ZDV receipt. Post hoc analysis revealed that being unmarried, Black, multiparous, having no insurance, and illegal drug use were associated with limited prenatal care. Although the U.S. has seen reductions in HIV perinatal transmission, our research showed that HIV-infected women who did not get prenatal care were less likely to receive two arms of ZDV prophylaxis. A wide public health net that brings all women into care is necessary to reduce perinatal transmission further.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677072     DOI: 10.1353/hpu.0.0039

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  2 in total

Review 1.  ART uptake and adherence among women who use drugs globally: A scoping review.

Authors:  Jennifer L Glick; Aimee Huang; Rienna Russo; Belinda Jivapong; Vijayasundaram Ramasamy; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2020-08-02       Impact factor: 4.492

2.  Presentation for care and antenatal management of HIV in the UK, 2009-2014.

Authors:  C E French; C Thorne; L Byrne; M Cortina-Borja; P A Tookey
Journal:  HIV Med       Date:  2016-08-01       Impact factor: 3.180

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.